Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.

Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a

Informations de copyright

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Déclaration de conflit d'intérêts

Conflict of Interest/Interessenkonflikt A. D. H. received speaker and consultancy honoraria from AstraZeneca, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi Sankyo, Hexal and Pfizer. F. O. received speaker and consultancy honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Chugai, Celgene, Cellex, Eisai, Gilead, Hexal, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Novonordisc, Riemser, Roche, Servier, Shire, Tesaro, Teva. H.-C. K. received honoraria from Carl Zeiss meditec, TEVA, Theraclion, Novartis, Amgen, Astra Zeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche and Genomic Health. P. A. F. received honoraria from Novartis, Pfizer, Roche, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Merck-Sharp & Dohme, Eisai, Puma and Teva. His institution conducts research with funding from Novartis and Biontech. H. T. received honoraria from Novartis, Roche, Celgene, Teva, Pfizer and travel support from Roche, Celgene and Pfizer. J. E. received honoraria from AstraZeneca, Roche, Celgene, Novartis, Lilly, Pfizer, Pierre Fabre, Teva, Daiichi-Sankyo and travel support from Astra, Celgene, Daiichi-Sankyo, Lilly, Novartis, Pfizer, Teva, Pierre Fabre. M. P. L. has participated on advisory boards for AstraZeneca, Lilly, MSD, Novartis, Pfizer, Eisai, Genomic Health and Roche and has received honoraria for lectures from MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca, medac and Eisai. V. M. received speaker honoraria from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Pfizer, Novartis, Roche, Teva, Janssen-Cilag and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi Sankyo and Eisai, Lilly, Tesaro and Nektar. E. B. received honoraria from Novartis, Hexal and onkowissen.de for consulting, clinical research management or medical education activities. A. S. received honoraria from Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH and promedicis GmbH. W. J. received honoraria and research grants from Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, Sanofi, Daichi, Tesaro. F. S. participated on advisory boards for Novartis, Lilly, Amgen and Roche and received honoraria for lectures from Roche, AstraZeneca, MSD, Novartis and Pfizer. A. W. participated on advisory boards for Novartis, Lilly, Amgen, Pfizer, Roche, Tesaro, Eisai and received honoraria for lectures from Novartis, Pfizer, Aurikamed, Roche, Celgene. D. L. received honoraria from Amgen, AstraZeneca, Celgene, Lilly, Loreal, MSD, Novartis, Pfizer, Tesaro, Teva T. N. F. has participated on advisory boards for Amgen, Daiichi Sankyo, Novartis, Pfizer, and Roche and has received honoraria for lectures from Amgen, Celgene, Daiichi Sankyo, Roche, Novartis and Pfizer. M. T. has participated on advisory boards for AstraZeneca, Lilly, MSD, Novartis, Pfizer, Genomic Health and Roche and has received honoraria for lectures from MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, and AstraZeneca M. W. has participated on advisory boards for AstraZeneca, Lilly, MSD, Novartis, Pfizer and Roche. J. H. reports receiving speakers bureau honoraria from Celgene, Novartis, and Roche, and is a consultant/advisory board member for Amgen, Celgene, Novartis and Roche./ A. D. H. hat von AstraZeneca, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi-Sankyo und Hexal und Pfizer Honorare für Referenten- und Beratungstätigkeiten erhalten. F. O. hat von Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Chugai, Celgene, Cellex, Eisai, Gilead, Hexal, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Novonordisc, Riemser, Roche, Servier, Shire, Tesaro und Teva Honorare für Referenten- und Beratungstätigkeiten erhalten. H.-C. K. hat von Carl Zeiss meditec, Teva, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche und Genomic Health Honorare erhalten. P. A. F. hat von Novartis, Pfizer, Roche, Amgen, Celgene, Daiichi-Sankyo, AstraZeneca, Merck-Sharp & Dohme, Eisai, Puma und Teva Honorare erhalten. Seine Institution betreibt Forschung mit finanzieller Unterstützung durch Novartis und Biontech. H. T. hat von Novartis, Roche, Celgene, Teva und Pfizer Honorare und von Roche, Celgene und Pfizer Reisebeihilfen erhalten. J. E. hat von AstraZeneca, Roche, Celgene, Novartis, Lilly, Pfizer, Pierre Fabre, Teva und Daiichi-Sankyo Honorare und von Astra, Celgene, Daiichi-Sankyo, Lilly, Novartis, Pfizer, Teva und Pierre Fabre Reisebeihilfen erhalten. M. P. L. hat für AstraZeneca, Lilly, MSD, Novartis, Pfizer, Eisai, Genomic Health und Roche in Beratungsgremien mitgewirkt und von MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca, medac und Eisai Vortragshonorare erhalten. V. M. hat von Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Pfizer, Novartis, Roche, Teva und Janssen-Cilag Honorare für Referententätigkeiten und von Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi Sankyo und Eisai, Lilly, Tesaro und Nektar Beratungshonorare erhalten. E. B. hat von Novartis, Hexal und onkowissen.de für Beratungstätigkeiten, Leitung klinischer Forschung oder medizinische Schulungsaktivitäten Honorare erhalten. A. S. hat von Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH und promedicis GmbH Honorare erhalten. W. J. hat von Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, Sanofi, Daichi und Tesaro Honorare und Forschungszuschüsse erhalten. F. S. hat für Novartis, Lilly, Amgen und Roche in Beratungsgremien mitgewirkt und von Roche, AstraZeneca, MSD, Novartis und Pfizer Vortragshonorare erhalten. A. W. hat für Novartis, Lilly, Amgen, Pfizer, Roche, Tesaro und Eisai in Beratungsgremien mitgewirkt und von Novartis, Pfizer, Aurikamed, Roche und Celgene Vortragshonorare erhalten. D. L. hat von Amgen, AstraZeneca, Celgene, Lilly, Loreal, MSD, Novartis, Pfizer, Tesaro und Teva Honorare erhalten. T. N. F. hat für Amgen, Daichi Sankyo, Novartis, Pfizer und Roche in Beratungsgremien mitgewirkt und von Amgen, Celgene, Daiichi Sankyo, Roche, Novartis und Pfizer Vortragshonorare erhalten. M. T. hat für AstraZeneca, Lilly, MSD, Novartis, Pfizer, Genomic Health und Roche in Beratungsgremien mitgewirkt und von MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health und AstraZeneca Vortragshonorare erhalten. M. W. hat für AstraZeneca, Lilly, MSD, Novartis, Pfizer und Roche in Beratungsgremien mitgewirkt. J. H. berichtet, von Celgene, Novartis, und Roche Honorare für Referententätigkeiten erhalten zu haben und ist Berater/Beiratsmitglied von Amgen, Celgene, Novartis und Roche.